Request Trial
cozy-nook-shuttersock-com
Cozy nook / Shuttersock.com
16 June 2016AsiaVikrant Rana and Sanjeeta Das

Case report: Biocon’s breast cancer biosimilar gets green light

The Division Bench of the Delhi High Court, in its order dated April 28, 2016, has allowed Indian biopharmaceutical company Biocon and its partner Mylan Pharmaceuticals to continue marketing their breast cancer drug trastuzumab until the next court hearing, on July 21, 2016. Mr Justice Badar Durrez Ahmed and Mr Justice Sanjeev Sachdeva delivered the ruling in the case of Biocon Limited v Roche Products (India) Private Limited & Ors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026   The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.
Asia
Chinese biotech strikes billion dollar deal in nextgen cancer race
20 January 2026   Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
Asia
Novo Nordisk secures China win ahead of key patent expiration
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
Abbott IP chief: ‘Firms without AI policies scare me’
Moderna inks billion-dollar deal to settle long-running Spikevax dispute
Emotional Perception: What next for patent holders?
LSPN Awards 2026 finalists revealed
Natera and a rival draw the line under five-year fight